HomeCompareANGN vs JNJ

ANGN vs JNJ: Dividend Comparison 2026

ANGN yields 200.00% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ANGN wins by $119.34M in total portfolio value
10 years
ANGN
ANGN
● Live price
200.00%
Share price
$1.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$119.36M
Annual income
$60,176,096.29
Full ANGN calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — ANGN vs JNJ

📍 ANGN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodANGNJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ANGN + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ANGN pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ANGN
Annual income on $10K today (after 15% tax)
$17,000.00/yr
After 10yr DRIP, annual income (after tax)
$51,149,681.85/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, ANGN beats the other by $51,148,978.23/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ANGN + JNJ for your $10,000?

ANGN: 50%JNJ: 50%
100% JNJ50/50100% ANGN
Portfolio after 10yr
$59.69M
Annual income
$30,088,462.03/yr
Blended yield
50.41%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

ANGN
Analyst Ratings
1
Buy
3
Hold
Consensus: Hold
Price Target
$1.50
+50.0% upside vs current
Range: $1.50 — $1.50
Altman Z
-16.3
Piotroski
3/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ANGN buys
0
JNJ buys
0
No recent congressional trades found for ANGN or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricANGNJNJ
Forward yield200.00%3.36%
Annual dividend / share$2.00$4.96
Payout ratio50%55%
1-year div growth0%4.2%
5-year div CAGR0%5.8%
Portfolio after 10y$119.36M$20.0K
Annual income after 10y$60,176,096.29$827.78
Total dividends collected$112.49M$5.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy
Analyst price target$1.50$228.73

Year-by-year: ANGN vs JNJ ($10,000, DRIP)

YearANGN PortfolioANGN Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$30,700$20,000.00$10,676$355.77+$20.0KANGN
2$90,232$57,383.18$11,407$389.39+$78.8KANGN
3$254,173$157,624.56$12,198$426.53+$242.0KANGN
4$686,927$414,961.74$13,056$467.62+$673.9KANGN
5$1,783,118$1,048,106.39$13,987$513.12+$1.77MANGN
6$4,450,613$2,542,677.12$14,998$563.56+$4.44MANGN
7$10,693,420$5,931,263.38$16,098$619.52+$10.68MANGN
8$24,760,608$13,318,648.86$17,295$681.69+$24.74MANGN
9$55,315,649$28,821,798.66$18,599$750.82+$55.30MANGN
10$119,363,841$60,176,096.29$20,022$827.78+$119.34MANGN

ANGN vs JNJ: Complete Analysis 2026

ANGNStock

Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases. The company's lead product candidate is ANG-3070, an oral tyrosine kinase receptor inhibitor in development as a treatment for fibrotic diseases, primarily in the kidney and lung. It also develops ANG-3777, a hepatocyte growth factor mimetic to treat acute organ injuries, such as delayed graft function; ROCK2 inhibitors programs for fibrotic diseases; and CYP11B2 inhibitor program. The company was incorporated in 1998 and is based in Uniondale, New York.

Full ANGN Calculator →

JNJHealthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this ANGN vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ANGN vs SCHDANGN vs JEPIANGN vs OANGN vs KOANGN vs MAINANGN vs ABBVANGN vs MRKANGN vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.